A Phase 3 interventional study of Nilotinib and Imatinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 7th largest by enrollment, is one of 4 that started in 2011, is one of 15 in phase 3, and was the 27th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 13th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 19 in phase 3, and was the 42nd registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented chronic phase CML will meet all the criteria defined by:
Adequate organ function as defined by:
Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Major Molecular Response (MMR) at 12 Months - With Imputation.
Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. This endpoint was calculated based on the 12 month analysis.
Time frame: 12 months
MMR Rate at Each Time Point
Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. These time points including the 12 month data were calculated based on the final analysis after the end of the study.
Time frame: Months 3,6,9,12,15, 18, 21, 24, 36
Best MMR by Each Timepoint
Best MMR rates by scheduled time point are cumulative response rates up to that time point. In this analysis, patients who had achieved MMR at or before the time point were counted as responders, no matter if they lost the response/discontinued or not. Therefore, this response rate represented the best observed response rate up to that specific time point.
Time frame: Months 3,6,9,12,15, 18, 21, 24, 36
Kaplan-Meier Estimates of Time to First MMR
Time to first MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375.
Time frame: End of study (up to 40 months)
Durable MMR Rate at 24 Months
The rate of durable MMR at 24 months, defined as the proportion of patients who have achieved MMR at 12 months, and also maintain continuous MMR until the 24 month time point (1 month = 28 days) without intervening loss of MMR in between 12 and 24 months
Time frame: 24 months
Kaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMR
Duration of first MMR (months) = (date of loss of MMR or censoring-date of first MMR + 1)/30.4375.
Time frame: End of Study (Up to 40 months)
Best Complete Cytogenic Response (CCyR) Rate by Each Time Point
CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics.
Time frame: Months 6, 12, 18, 30, 24, 36
Kaplan-Meier Estimates of Time to First CCYR
Time to first CCyR (months) = (date of first CCyR - date of randomization + 1) / 30.4375.
Time frame: End of study (up to 40 months)
Kaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyR
Duration of CCyR (months) = (date of CCyR loss or censoring-date of first CCyR + 1)/30.4375
Time frame: End of Study (up to 40 months)
Kaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on Treatment
Time to progression to AP/BC was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of CML-related death, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or CML-related deaths occurring on treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease, or cytogenetic evaluation) in the study for patients without event. * On-study: included progressions to AP/BC or CML-related deaths occurring in the study or during the follow-up period after discontinuation of treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment
Time frame: End of study (up to 40 months)
Kaplan-Meier Estimates of Event-free Survival (EFS) on Treatment
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following:-Death due to any cause, - Progression to AP or BC, Loss of partial cytogenetic response (PCyR), - Loss of CCyR, - Loss of CHR
Time frame: End of Study (up to 40 months)
Kaplan-Meier Estimates of Progression-free Survival (PFS) on Treatment
Progression-free survival was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of death from any cause, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or deaths occurring only on-treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease or cytogenetic evaluation) in the study before the cut-off date of the analysis for patients without event. * On-study: included progressions to AP/BC or deaths occurring in the study or during the follow-up period after discontinuation of study treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment.
Time frame: End of study (up to 40 months)
Kaplan-Meier Estimates of Overall Survival (OS) on Treatment
Patients who discontinued study treatment early or completed the study protocol and did not enter into the extension protocol were to be followed for survival every 3 months for up to 2 calendar years from the date the last patient randomized received the first dose of study drug and every 6 months until Last Patient Last Visit. Overall survival (all deaths) was defined as the time between date of randomization and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment, i.e. overall survival on-study. The time was censored at the date of last assessment in the study for patients who are still being treated and at the date of last contact for patients who discontinued treatment.
Time frame: End of Study (up to 40 months)
Best Complete Hematologic Response (CHR)
CHR was defined as having all of the following criteria present at any assessment, which was confirmed by another assessment at least after 4 weeks: • WBC count \< 10 x 10E9 /L • Platelet count \< 450 x 10E9 /L • Basophils \< 5% • No blasts and promyelocytes in peripheral blood • Myelocytes + metamyelocytes \< 5 % in peripheral blood • No evidence of extramedullary involvement. The assessment was not considered CHR, if there were any values indicative of CML in AP or BC (i.e. by blasts in bone marrow). For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 weeks after the initial assessment) had to satisfy all criteria mentioned above, without any assessment in between which indicated 'No response'.
Time frame: Months 1, 3, 4, 5, 6, 9,12, 15,18, 21, 24, 30, 36
Modified ELN2009 Criteria
Patients satisfying criteria for several "modified ELN 2009" categories are presented once under the worst category (Optimal\> Suboptimal \> Treatment failure). Patients in the "Discontinued" category are those who discontinued before the time point considered without satisfying any of the ELN 2009 criteria. Patients in the "Missing" category are those ongoing in the trial at the time point considered but with only missing or non evaluable data for ELN 2009 criteria.
Time frame: End of Study (up to 40 months)
Actual Dose Intensity
Total dose/time on treatment (periods of zero dose were included).
Time frame: End of Study (up to 40 months)
Summary Statistics of Trough Imatinib and Major Metabolite CGP74588 of Imatinib and Nilotinib PK Concentration by Time Point
Pharmacokinetic Analysis Set
Time frame: 12 Months
| Milestone | Imatinib | Nilotinib |
|---|---|---|
| Started | 133 | 134 |
| Intended to continue into extension | 112 | 113 |
| Completed | 113 | 113 |
| Not completed | 20 | 21 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Disease progression | 6 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Suboptimal response/treatment failure | 5 | 6 |
Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. This endpoint was calculated based on the 12 month analysis.
| Percentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| Major Molecular Response (MMR) at 12 Months - With Imputation. | 27.8 (20.4 to 36.3) | 52.2 (43.4 to 60.9) |
Major molecular response (MMR) was defined as a value of ≤ 0.1% of BCR-ABL ratio on the IS. The minimum number of control genes for a sample to be valid was 3000. For statistical comparison purpose, MMR was considered as a binary variable with patients achieving MMR grouped as 'responders' and patients not achieving MMR, patients with missing PCR evaluations or patients with atypical transcripts at baseline grouped as 'non-responders'. These time points including the 12 month data were calculated based on the final analysis after the end of the study.
| Percentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| 3 Months | 3.0 (0.8 to 7.5) | 13.4 (8.2 to 20.4) |
| 6 Months | 18.0 (11.9 to 25.6) | 44.8 (36.2 to 53.6) |
| 9 Months | 21.1 (14.5 to 29.0) | 47.8 (39.1 to 56.6) |
| 12 Months | 27.8 (20.4 to 36.3) | 53.0 (44.2 to 61.7) |
| 15 Months | 36.1 (27.9 to 44.9) | 59.0 (50.1 to 67.4) |
| 18 Months | 40.6 (32.2 to 49.5) | 57.5 (48.6 to 66.0) |
| 21 Months | 41.4 (32.9 to 50.2) | 61.9 (53.2 to 70.2) |
| 24 Months | 49.6 (40.8 to 58.4) | 61.9 (53.2 to 70.2) |
| 36 Months | 59.4 (50.5 to 67.8) | 68.7 (60.1 to 76.4) |
Best MMR rates by scheduled time point are cumulative response rates up to that time point. In this analysis, patients who had achieved MMR at or before the time point were counted as responders, no matter if they lost the response/discontinued or not. Therefore, this response rate represented the best observed response rate up to that specific time point.
| Percentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| Overall | 66.9 (58.2 to 74.8) | 73.9 (65.6 to 81.1) |
| Month 3 | 3.0 (0.8 to 7.5) | 13.4 (8.2 to 20.4) |
| Month 6 | 18.0 (11.9 to 25.6) | 45.5 (36.9 to 54.3) |
| Month 9 | 22.6 (15.8 to 30.6) | 51.5 (42.7 to 60.2) |
| Month 12 | 30.8 (23.1 to 39.4) | 56.0 (47.1 to 64.5) |
| Month 15 | 37.6 (29.3 to 46.4) | 62.7 (53.9 to 70.9) |
| Month 18 | 42.9 (34.3 to 51.7) | 64.2 (55.4 to 72.3) |
| Month 21 | 46.6 (37.9 to 55.5) | 66.4 (57.8 to 74.3) |
| Month 24 | 52.6 (43.8 to 61.3) | 67.9 (59.3 to 75.7) |
| Month 36 | 65.4 (56.7 to 73.4) | 73.9 (65.6 to 81.1) |
Time to first MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375.
| months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Time to First MMR | 21.7 (16.5 to 25.2) | 8.1 (5.6 to 11.1) |
The rate of durable MMR at 24 months, defined as the proportion of patients who have achieved MMR at 12 months, and also maintain continuous MMR until the 24 month time point (1 month = 28 days) without intervening loss of MMR in between 12 and 24 months
| Perentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| Durable MMR Rate at 24 Months | 27.8 (20.4 to 36.3) | 50.7 (42.0 to 59.5) |
Duration of first MMR (months) = (date of loss of MMR or censoring-date of first MMR + 1)/30.4375.
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Duration of First MMR Among Patients Who Achieved MMR | NA (NA to NA) | NA (NA to NA) |
CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics.
| Percentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| Overall | 89.5 (83.0 to 94.1) | 85.8 (78.7 to 91.2) |
| Month 6 | 57.1 (48.3 to 65.7) | 66.4 (57.8 to 74.3) |
| Month 12 | 80.5 (72.7 to 86.8) | 77.6 (69.6 to 84.4) |
| Month 18 | 84.2 (76.9 to 90.0) | 80.6 (72.9 to 86.9) |
| Month 30 | 88.0 (81.2 to 93.0) | 84.3 (77.0 to 90.0) |
| Month 24 | 86.5 (79.5 to 91.8) | 83.6 (76.2 to 89.4) |
| Month 36 | 89.5 (83.0 to 94.1) | 85.8 (78.7 to 91.2) |
Time to first CCyR (months) = (date of first CCyR - date of randomization + 1) / 30.4375.
| months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Time to First CCYR | 6.1 (5.6 to 6.6) | 5.6 (5.6 to 6.2) |
Duration of CCyR (months) = (date of CCyR loss or censoring-date of first CCyR + 1)/30.4375
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Duration of First CCyR Among Patients Who Achieved CCyR | NA (NA to NA) | NA (NA to NA) |
Time to progression to AP/BC was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of CML-related death, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or CML-related deaths occurring on treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease, or cytogenetic evaluation) in the study for patients without event. * On-study: included progressions to AP/BC or CML-related deaths occurring in the study or during the follow-up period after discontinuation of treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Time to Progression to Accelerated Phase/Blast Crisis (AP/BC) on Treatment | NA (NA to NA) | NA (NA to NA) |
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following:-Death due to any cause, - Progression to AP or BC, Loss of partial cytogenetic response (PCyR), - Loss of CCyR, - Loss of CHR
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Event-free Survival (EFS) on Treatment | NA (NA to NA) | NA (NA to NA) |
Progression-free survival was defined as the time from the date of randomization to the date of event defined as the first disease progression to AP/BC or the date of death from any cause, whichever is earlier. This variable was analyzed in 2 ways: * On-treatment: included progressions to AP/BC or deaths occurring only on-treatment in the study as events. The time was censored at the date of last on-treatment assessment (hematology, extramedullary disease or cytogenetic evaluation) in the study before the cut-off date of the analysis for patients without event. * On-study: included progressions to AP/BC or deaths occurring in the study or during the follow-up period after discontinuation of study treatment as events. The time was censored at the last assessment date in the study for patients who were still being treated and at the date of last contact for patients who discontinued treatment.
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Progression-free Survival (PFS) on Treatment | NA (NA to NA) | NA (NA to NA) |
Patients who discontinued study treatment early or completed the study protocol and did not enter into the extension protocol were to be followed for survival every 3 months for up to 2 calendar years from the date the last patient randomized received the first dose of study drug and every 6 months until Last Patient Last Visit. Overall survival (all deaths) was defined as the time between date of randomization and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment, i.e. overall survival on-study. The time was censored at the date of last assessment in the study for patients who are still being treated and at the date of last contact for patients who discontinued treatment.
| Months | Imatinib | Nilotinib |
|---|---|---|
| Kaplan-Meier Estimates of Overall Survival (OS) on Treatment | NA (NA to NA) | NA (NA to NA) |
CHR was defined as having all of the following criteria present at any assessment, which was confirmed by another assessment at least after 4 weeks: • WBC count \< 10 x 10E9 /L • Platelet count \< 450 x 10E9 /L • Basophils \< 5% • No blasts and promyelocytes in peripheral blood • Myelocytes + metamyelocytes \< 5 % in peripheral blood • No evidence of extramedullary involvement. The assessment was not considered CHR, if there were any values indicative of CML in AP or BC (i.e. by blasts in bone marrow). For confirmation of CHR, both the initial CHR as well as the confirming assessment (at least 4 weeks after the initial assessment) had to satisfy all criteria mentioned above, without any assessment in between which indicated 'No response'.
| Percentage of participants | Imatinib | Nilotinib |
|---|---|---|
| Overall | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
| Month 1 | 66.2 (57.5 to 74.1) | 73.1 (64.8 to 80.4) |
| Month 3 | 91.0 (84.8 to 95.3) | 91.8 (85.8 to 95.8) |
| Month 4 | 93.2 (87.5 to 96.9) | 93.3 (87.6 to 96.9) |
| Month 5 | 94.0 (88.5 to 97.4) | 93.3 (87.6 to 96.9) |
| Month 6 | 94.7 (89.5 to 97.9) | 93.3 (87.6 to 96.9) |
| Month 9 | 94.7 (89.5 to 97.9) | 93.3 (87.6 to 96.9) |
| Month 12 | 94.7 (89.5 to 97.9) | 94.0 (88.6 to 97.4) |
| Month 15 | 94.7 (89.5 to 97.9) | 94.0 (88.6 to 97.4) |
| Month 18 | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
| Month 21 | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
| Month 24 | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
| Month 30 | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
| Month 36 | 94.7 (89.5 to 97.9) | 94.8 (89.5 to 97.9) |
Patients satisfying criteria for several "modified ELN 2009" categories are presented once under the worst category (Optimal\> Suboptimal \> Treatment failure). Patients in the "Discontinued" category are those who discontinued before the time point considered without satisfying any of the ELN 2009 criteria. Patients in the "Missing" category are those ongoing in the trial at the time point considered but with only missing or non evaluable data for ELN 2009 criteria.
| Percentage of Participants | Imatinib | Nilotinib |
|---|---|---|
| Optimal Response | 39.8 | 55.2 |
| Suboptimal Response | 41.4 | 24.6 |
| Treatment Failure | 16.5 | 14.9 |
| Discontinued | 2.3 | 5.2 |
Total dose/time on treatment (periods of zero dose were included).
| mg/day | Imatinib | Nilotinib |
|---|---|---|
| Actual Dose Intensity | 416.0 ± 62.40 | 536.4 ± 99.07 |
Pharmacokinetic Analysis Set
| ng/mL | Imatinib | CGP74588 | Nilotinib |
|---|---|---|---|
| Day 8 (Cycle 1) | 1235.3 ± 632.36 | 255.4 ± 154.74 | 1036.8 ± 618.10 |
| Day 28 (Cycle 1) | 1291.3 ± 553.44 | 288.9 ± 130.25 | 970.4 ± 606.89 |
| Day 84 (Cycle 3) | 1137.8 ± 461.50 | 235.7 ± 104.31 | 1172.4 ± 656.25 |
| Day 168 (Cycle 6) | 1078.2 ± 413.99 | 243.2 ± 88.66 | 1154.8 ± 1034.15 |
| Day 336 (Cycle 12) | 1111.1 ± 434.85 | 238.7 ± 89.11 | 1370.5 ± 878.88 |
| Average trough PK | 1188.7 ± 452.24 | 258.7 ± 112.88 | 1137.4 ± 631.31 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib 400 mg qd | — | 13/132 (9.8%) | 124/132 (93.9%) |
| Nilotinib 300 mg Bid | — | 11/133 (8.3%) | 131/133 (98.5%) |
| Event | Imatinib 400 mg qd | Nilotinib 300 mg Bid |
|---|---|---|
| Bone marrow failureBlood and lymphatic system disorders | 1/132 | 3/133 |
| Platelet count decreasedInvestigations | 0/132 | 3/133 |
| GranulocytopeniaBlood and lymphatic system disorders | 1/132 | 0/133 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/132 | 0/133 |
| Thrombocytopenic purpuraBlood and lymphatic system disorders | 1/132 | 0/133 |
| ThrombocytosisBlood and lymphatic system disorders | 1/132 | 0/133 |
| Anal abscessInfections and infestations | 1/132 | 0/133 |
| Ankle fractureInjury, poisoning and procedural complications | 1/132 | 0/133 |
| Blast cell count increasedInvestigations | 1/132 | 0/133 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/132 | 0/133 |
| Event | Imatinib 400 mg qd | Nilotinib 300 mg Bid |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 17/132 | 47/133 |
| ThrombocytopeniaBlood and lymphatic system disorders | 37/132 | 41/133 |
| Blood bilirubin increasedInvestigations | 8/132 | 41/133 |
| HyperbilirubinaemiaHepatobiliary disorders | 4/132 | 40/133 |
| Lipase increasedInvestigations | 29/132 | 37/133 |
| LeukopeniaBlood and lymphatic system disorders | 35/132 | 27/133 |
| Platelet count decreasedInvestigations | 30/132 | 23/133 |
| White blood cell count decreasedInvestigations | 28/132 | 16/133 |
| Alanine aminotransferase increasedInvestigations | 16/132 | 28/133 |
| Eyelid oedemaEye disorders | 25/132 | 4/133 |
| Age, Continuous(Years) | Imatinib | Nilotinib | Total |
|---|---|---|---|
| Mean | 39.7 ± 12.86 | 41.5 ± 12.76 | 40.6 ± 12.82 |
| Sex: Female, Male(Participants) | Imatinib | Nilotinib | Total |
|---|---|---|---|
| Female | 52 | 43 | 95 |
| Male | 81 | 91 | 172 |
The record gives a start of Apr 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →